Literature DB >> 28842225

Transvenous lead extraction at the time of cardiac implantable electronic device upgrade: Complexity, safety, and outcomes.

Amr F Barakat1, Oussama M Wazni2, Khaldoun Tarakji2, Walid I Saliba2, Nayef Nimri1, John Rickard2, Michael Brunner2, Mandeep Bhargava2, Mohamed Kanj2, Bryan Baranowski2, David O Martin2, Daniel Cantillon2, Thomas Callahan2, Thomas Dresing2, Mark Niebauer2, Mina Chung2, Bruce D Lindsay2, Bruce Wilkoff2, Ayman A Hussein3.   

Abstract

BACKGROUND: The practice of lead abandonment at the time of cardiac implantable electronic device upgrade remains a controversial topic but is affecting an increasing number of patients. Inherent risks include high-risk extractions of redundant leads when extraction is required at a later date.
OBJECTIVES: We aimed to report our experience with transvenous lead extraction (TLE) at the time of device upgrade.
METHODS: All consecutive TLE procedures at the time of device upgrade at the Cleveland Clinic between January 1, 1996 and December 31, 2012 were included (n = 503). Success and complications were defined according to the Heart Rhythm Society consensus document on TLE.
RESULTS: There were a total of 984 leads in place, and 719 were targeted with extraction (589 pacer and 130 defibrillator leads, 63 of them being dual-coil leads). In all patients, TLEs aimed to avoid abandoning leads. Concomitant lead management issues included lead malfunction (15%), previously abandoned leads (9%), vascular access occlusion (6%), or leads on advisory (3%). In most procedures (75.4%), special extraction tools were needed. The complete procedural and clinical success rates were 96.6% and 97.2%, respectively. During planned extractions, damage of coexisting leads occurred in 19 patients (3.8%), eventually requiring extraction. The major and minor complication rates were 1% and 1.4%, respectively.
CONCLUSION: In a high-volume center, TLEs at the time of device upgrade were successful in the vast majority of patients with a low complication rate.
Copyright © 2017. Published by Elsevier Inc.

Entities:  

Keywords:  CIED upgrade; Implantable cardioverter-defibrillator; Lead extraction; Outcome; Pacemaker

Mesh:

Year:  2017        PMID: 28842225     DOI: 10.1016/j.hrthm.2017.08.019

Source DB:  PubMed          Journal:  Heart Rhythm        ISSN: 1547-5271            Impact factor:   6.343


  6 in total

1.  Experience of cardiac implantable electronic device lead removal from a South African tertiary referral centre.

Authors:  Philasande Mkoko; Nicholus Xolani Mdakane; Glenda Govender; Jacques Scherman; Ashley Chin
Journal:  Cardiovasc J Afr       Date:  2021-04-19       Impact factor: 1.167

Review 2.  New Insights in Central Venous Disorders. The Role of Transvenous Lead Extractions.

Authors:  Giulia Domenichini; Mathieu Le Bloa; Patrice Carroz; Denis Graf; Claudia Herrera-Siklody; Cheryl Teres; Alessandra Pia Porretta; Patrizio Pascale; Etienne Pruvot
Journal:  Front Cardiovasc Med       Date:  2022-02-23

3.  Reintervention in Artificial Cardiac Pacing Systems.

Authors:  Silas Dos Santos Galvão Filho
Journal:  Arq Bras Cardiol       Date:  2018-11       Impact factor: 2.000

4.  Transesophageal Echocardiography As a Monitoring Tool During Transvenous Lead Extraction-Does It Improve Procedure Effectiveness?

Authors:  Dorota Nowosielecka; Wojciech Jacheć; Anna Polewczyk; Łukasz Tułecki; Konrad Tomków; Paweł Stefańczyk; Andrzej Tomaszewski; Wojciech Brzozowski; Dorota Szcześniak-Stańczyk; Andrzej Kleinrok; Andrzej Kutarski
Journal:  J Clin Med       Date:  2020-05-08       Impact factor: 4.241

5.  Transvenous Lead Extraction SAFeTY Score for Risk Stratification and Proper Patient Selection for Removal Procedures Using Mechanical Tools.

Authors:  Wojciech Jacheć; Anna Polewczyk; Maciej Polewczyk; Andrzej Tomasik; Andrzej Kutarski
Journal:  J Clin Med       Date:  2020-01-28       Impact factor: 4.241

6.  Transvenous Lead Extraction without Procedure-Related Deaths in 1000 Consecutive Patients: A Single-Center Experience.

Authors:  Paweł Stefańczyk; Dorota Nowosielecka; Łukasz Tułecki; Konrad Tomków; Anna Polewczyk; Wojciech Jacheć; Andrzej Kleinrok; Wojciech Borzęcki; Andrzej Kutarski
Journal:  Vasc Health Risk Manag       Date:  2021-08-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.